Vidhya Nair, DO
Hematology & Oncology · Seattle, WANPI 1790214997
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,020 of the $9,274 with a category attached, or 64.9%. Gilead accounts for 83.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2024 at $8,085 and has fallen 95.1% since, to $396 in 2025.
Across 25 payments — averaging $370.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$8K
- Seagen Inc.$483
- AstraZeneca$350
- Stemline Therapeutics Inc.$328
- Incyte Corporation$252
- Genentech USA, Inc.$68
- plus $59 from 1 others
What the payments were for
- Consulting fees$6,02065%
- Grants$3504%
- Travel & lodging$1,23413%
- Food & beverage$1,67018%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 12 | $7,735 |
| Seagen Inc. | 4 | $483 |
| AstraZeneca | 1 | $350 |
| Stemline Therapeutics Inc. | 4 | $328 |
| Incyte Corporation | 2 | $252 |
| Genentech USA, Inc. | 1 | $68 |
| ADC Therapeutics America, Inc. | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,274 in reported general payments places this provider in the 75th percentile of 349 hematology & oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 16 | $727 |
| Letrozole | 25 | $574 |
| Anastrozole | 11 | $335 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Celestia HiganoSeattle$164K
- Ryan CassadaySeattle$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.